Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Phase III Data For Teva Pharmaceutical Industries Ltd's QNASL (Beclomethasone Dipropionate) Demonstrate Efficacy Profile In Pediatric Patients With Seasonal Allergic Rhinitis


Friday, 9 Nov 2012 08:00am EST 

Teva Pharmaceutical Industries Ltd announced additional data from the Phase III clinical program for QNASL (beclomethasone dipropionate) Nasal Aerosol, highlighting the drug`s efficacy profile in treating children (ages 6-11) with nasal symptoms of seasonal allergic rhinitis (SAR). QNASL is a nonaqueous, "dry" nasal aerosol corticosteroid currently approved for the treatment of nasal symptoms associated with SAR and perennial allergic rhinitis (PAR) in patients aged 12 years and older. The data are being presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA. Additional data also presented at the ACAAI meeting reinforce the long-term ocular safety profile of QNASL and the functionality and reliability of the device. Highlights from a study evaluating ocular safety following long-term (52-week) treatment of QNASL (beclomethasone dipropionate) 320 mcg once-daily were also presented at ACAAI. The primary endpoint, which was previously reported2, showed statistically significant improvements in patient-reported 24-hour rTNSS in patients with PAR, aged 12 years and older, over the first 30 weeks of treatment. Data presented on November 09, 2012 demonstrate that at 30 and 52 weeks, there were no clinically important differences in intraocular pressure (IOP), which refers to the fluid pressure within the eye, between QNASL and placebo.